title: Cost-utility analysis of pacemakers for the treatment of vasovagal syncope.
abstract: Dual-chamber pacing is a promising treatment for patients with very frequent vasovagal syncope, but its cost utility is unknown. We report that the incremental cost per quality-adjusted life-year gained is $13,159 Canadian dollars (about $8,600 US dollars), and therefore this pacemaker therapy for vasovagal syncope has a favorable cost-utility ratio.
authors.affiliation: Health Research Group, University of Calgary, Alberta, Canada.
authors.forename: C R
authors.initials: CR
authors.lastname: Mitton
authors.forename: M S
authors.initials: MS
authors.lastname: Rose
authors.forename: M L
authors.initials: ML
authors.lastname: Koshman
authors.forename: R S
authors.initials: RS
authors.lastname: Sheldon
mesh_terms: D000328:Adult; D002170:Canada; D002304:Cardiac Pacing, Artificial / Q000191:economics* / Q000706:statistics & numerical data; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D005260:Female; D006801:Humans; D008297:Male; D010138:Pacemaker, Artificial / Q000191:economics* / Q000706:statistics & numerical data; D011788:Quality of Life; D055502:Secondary Prevention; D019462:Syncope, Vasovagal / Q000191:economics* / Q000628:therapy*